Summary: A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.
Minnerup J, Schäbitz W. Darbepoetin alfa and chronic kidney disease. N Engl J Med. 2010;362:653-4; author reply 655 pubmed
Marsden P. Treatment of anemia in chronic kidney disease--strategies based on evidence. N Engl J Med. 2009;361:2089-90 pubmed publisher
Winkelmayer W. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011;22:1-2 pubmed publisher
Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, et al
. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25:2779-2786 pubmed publisher
..iron versus intravenous iron in increasing hemoglobin in anemic cancer patients receiving chemotherapy and darbepoetin alfa, as well as safety, need of transfusion, and quality of life (QoL)...
Unger E, Thompson A, Blank M, Temple R. Erythropoiesis-stimulating agents--time for a reevaluation. N Engl J Med. 2010;362:189-92 pubmed publisher
Forni V, Bianchi G, Ogna A, Salvadé I, Vuistiner P, Burnier M, et al
. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrol. 2013;14:157 pubmed publisher
..Four subcutaneous treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other...
Steensma D, Sasu B, Sloan J, Tomita D, Loprinzi C. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood. 2015;125:3669-71 pubmed publisher
Saglimbene V, Palmer S, Ruospo M, Natale P, Craig J, Strippoli G. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2017;8:CD009904 pubmed publisher
..To assess benefits and harms of CERA compared with other epoetins (darbepoetin alfa and epoetin alfa or beta) or placebo/no treatment or CERA with differing strategy of administration for ..
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al
. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;:CD007303 pubmed publisher
..42). ESA treatment in cancer patients increased on study mortality and worsened overall survival. For patients undergoing chemotherapy the increase was less pronounced, but an adverse effect could not be excluded. ..